Safety Assessment in Drug Discovery and Development
The course is given every second year. The latest course was on 26-30 September, 2016. Next course dates will be announced here later.
The course is organised by the Advanced International Training Programme in Health Risk Assessment at IMM in collaboration with the Doctoral programme Environmental Factors and Health (EFH) at Karolinska Institutet, course number 2821 and the Executive and Professional Education Office at Karolinska Institutet.
The course corresponds to 1.5 ECTS credits.
After the course the student should be able to: discuss the role of safety assessment during the drug discovery and development process; evaluate how animal and human data can affect the decision to pursue or discontinue a drug project; identify important parameters when going from preclinical to clinical studies; and critically discuss how predictive methods could affect the drug discovery and development process.
The course identifies the different steps of the entire process of drug discovery and development, and the critical role played by safety assessment in a drug project moving through that process. The students will discuss and practice the assessments needed during the discovery and development phases, as well as the post-marketing phase. The importance of a safety assessment during target identification is highlighted, and special emphasis is put on how to include and evaluate toxicologically relevant in silico, in vitro and in vivo methods into a drug project during the discovery phase. The regulatory requirements, covering both pre-clinical and clinical studies in the development phase, are explored, with the aim to enable the students to put animal and human data into a regulatory context. Translational safety assessment, which bridges the gap between animal and human studies, is a special focus area. New relevant methods (such as adverse outcome pathways and non-animal methods), enabling a predictive approach to the process, are introduced. The occurrence and importance of pharmaceuticals in the environment is discussed.
Teaching and learning activities
The course consists of lectures, discussions and group assignments.
The course programme for the previous course on 26-30 September, 2016 is available here.
The course is intended for PhD students and other participants from academia as well as participants from authorities and industry.
There is no course fee for PhD students. The fee for participants from academia (except PhD students) is 300 euro, from authorities 600 euro and from industry 900 euro, including VAT. Course fee includes course material, coffee breaks and a get together reception. Payment of course fee can only be accepted from the participant’s employer, not from individuals.
The participants must cover their costs for travel and accommodation.
Information on application procedure to the next course will be available later.
Annika Hanberg, Institute of Environmental Medicine, Karolinska Institutet and Charlotte Nilsson, Swetox.